Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort

作者：JingSi Jiang, Xiaogang Li, Yuxin Mi, Yiying Wang, YanXi Heng, Zhiwen Li, Min Deng · 发表于：Neurodegenerative Disease Management · 年份：2025 · DOI：10.1080/17582024.2025.2488235 · 被引用次数：4 · 研究领域：Amyotrophic Lateral Sclerosis Research、Genetic Neurodegenerative Diseases、Multiple Sclerosis Research Studies

Aims This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).Patients & methods Propensity score matching was used to balance baseline variables between the riluzole group (n = 238) and control group (n = 454). Survival was analyzed using Kaplan – Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.Results Riluzole did not significantly improve survival (p = 0.478) or ALSFRS changes at 6 months (p = 0.380) or 12 months (p = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.Conclusions Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.